US-based precision medicine platform developer GNS Healthcare has raised $6m from Amgen Ventures, the corporate venturing vehicle for pharmaceutical company Amgen, and life sciences real estate trust Alexandria Real Estate Equities.
GNS is developing a machine learning and simulation platform that will be able to be used in drug discovery and development as well as healthcare management and business optimisation for health systems.
The company’s last funding had consisted of $4m provided by undisclosed investors in November 2016, according to a securities filing, six months after healthcare provider Horizon Healthcare Services invested an undisclosed sum in GNS.
Alexandria Real Estate Equities, pharmaceutical firm Celgene, diversified conglomerate Mitsui, health insurer Cambia Health Solutions, care providers Heritage Provider Network, and Gi Global Health Fund provided $10m in series C funding for GNS in late 2015.
Cambia Health had been a GNS investor since its $5m series A round in 2012, and returned for the company’s $10m series B in 2014 alongside Heritage Provider Network and Mitsui.
Pharmaceutical company Zambon, private equity firm GHO Capital and venture capital firm Fort Rock Capital are also investors in GNS, the company said in a press release announcing the latest funding.
Colin Hill, chairman and CEO of GNS, said: “We are witnessing an acceleration in the use of artificial intelligence and machine learning across all industries with GNS leading the way in the life sciences and healthcare industries with data from tens of millions of lives being processed by our platforms.
“This is the path to better matching drugs and other health interventions to individual patients to improve health outcomes, slow disease progression, and lower the total cost of care.”